Scientists Working Toward a Resistance-Proof Antiviral That Can Treat Many Diseases

Article

Scientists and health officials are marshaling forces to fight Zika, the latest in a string of recent outbreaks. Many of these efforts target that virus specifically, but some researchers are looking for a broader approach. Now one team reports in ACS' journal Macromolecules a new strategy to fight a wide range of viruses that appears to be safe in vivo and could evade a virus's ability to develop resistance.

Viruses are wily foes. They come in different forms, mutate rapidly and develop resistance to drugs easily. To fight them, scientists have largely attempted to tackle them one by one. But there are still no treatments for many viral infections, such as dengue and Ebola, even though some have been around for decades. A new approach aims to act more broadly against multiple viruses and involves targeting both viral surfaces and human cells. This strategy could also stop the pathogens in a way that could avoid the development of resistance. But so far, these methods have been toxic to healthy mammalian cells. Yi Yan Yang, Naoki Yamamoto, James Hedrick and colleagues wanted to find a safer method.

The researchers started with a polymer, called polyethylenimine (PEI), that had prevented viral infection through electrostatic interactions in previous studies. The PEI in those studies, however, was toxic to cells. So Yang and her collaborators modified it with mannose, a kind of sugar. The resulting complex interacted with the surfaces of both viral and human cells, and thus blocked the viruses from infecting the cells in lab testing. The researchers say this interaction can happen regardless of mutations and would make it difficult for a pathogen to sidestep. After two weeks of testing in an animal model, the modified PEI showed no toxic effects.

The authors acknowledge funding from the Institute of Bioengineering and Nanotechnology, the National University of Singapore and the IBM Almaden Research Center.

Source: American Chemical Society

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content